Shi-Wen Jiang, M.D., M.Sc.

  • JiangMember, Curtis and Elizabeth Anderson Cancer Institute
    Department of Laboratory Oncology Research
    Associate Professor, Department of Biomedical Sciences, Mercer University School of Medicine – Savannah Campus, Distinguished Cancer Scholar, State of Georgia

    912-350-0411 (phone)
    912-350-1269 (fax)
    Jiang_s@mercer.edu


    Research Focus

    The epigenetic regulation of gene expression in endometrial cancers. Epigenetics refers to the stable, somatically inheritable traits controlled by DNA/protein modifications rather than by alterations in DNA sequences, or genetic mutation. Epigenetic changes exert their effects on a variety of cell functions, and are frequently found in all the cancers studied. Specifically, Jiang’s studies concern the following areas:

    • Characterizing the targeting mechanisms of DNA methyltranferase, especially the establishment of cancer-specific methylation patterns and their role(s) in cancer progression.
    • Identification of epigenetic biomarkers that can be used for early diagnosis of endometrial cancer.
    • Preclinical studies on the chemotherapeutic application of epigenetic inhibitors for the treatment of endometrial cancers.

    In collaboration with Merck Pharmaceuticals, the laboratory is testing multiple HDAC and DNMT inhibitors using cell culture and in vivo animal models. Results have shown that small molecule HDAC inhibitory compounds are capable of sensitizing refractory endometrial cancer cells to progestational therapy. Moreover, a combination strategy using HDAC inhibitor and taxel significantly enhanced the anti-cancer effects and at the same time, may reduce the side effect of these drugs.

    Biography

    Shi-Wen (Albert) Jiang, M.D., M.Sc., earned his medical degree and his master of biomedical science degree at Beijing University School of Medicine in China. He then completed his postdoctoral training in the Endocrine Research Unit, Department of Internal Medicine, Mayo Medical School in Rochester, Minnesota. Jiang has 40 published papers in peer-reviewed research journals. He mentors and advises numerous M.D. and Ph.D. students, research fellows, and clinical residents/fellows. He also serves as editor and reviewer for a number of research journals and publications. Jiang has been invited to lecture in national and international venues.

    His research has attracted extramural funding from multiple sources including NIH R01, Gynecologic Cancer Foundation, NIHK08, NIH/NCI Endometrial Cancer SPORE Program, Merck Pharmaceuticals, and Eagles Cancer Research Fund. In addition, Jiang is a Georgia Cancer Coalition Distinguished Cancer Scientist.

    Recent Publications
    Singh BN, Hwa YL, Li J, Sean SC, Dowdy, Jiang S-W. (2010) Acetylation of Non-histone proteins as potential target for cancer therapy. Expert Review of Anti-cancer Therapy. 10(6):935-54.

    Li J, Dowdy SC, Trapton T, Podratz KC, Lu W-G, Xie X, Jiang S-W. (2009) HE4 as a biomarker for ovarian and endometrial cancer management. Expert Review of Molecular Diagnostics. 9:555-566.

    Jiang S-W, li J, Podratz KC, Dowdy SC (2008), Applications of DNA methylation biomarkers for endometrial cancer management. Expert Review of Molecular Diagnostics. 8:607-616.

    Li J, Wang E, Lau J, Jiang S-W, Datta K, Mukhopadhyay D. (2007), PKC-mediated modulation of factor inhibiting HIF-1(FIH-1) expression by the homeodomain proteing CDP/Cut/Cux. Molecular and Cellular Biology. 27:7345-7353.

    Jian S, Dowdy SC, Meng XW, Wang Z, We S, Jones MB, Podratz KC, Jiang S-W. (2007), Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells. Gynecologic Oncology. 105:493-500.

    Dowdy SC, Jiang S, Zhou C, Hou X, Fan J, Podratz KC, Jiang S-W. (2006), Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in endometrial cancer cells. Molecular Cancer Therapeutics. 5:2767-2776.

    Xiong YN, Dowdy SC, Podratz KC, Jin F, Attewell JR, Eberhardt NL, Jiang S-W. (2005), Histone deacetylase inhibitors decrease DNMT3B mRNA stability and downregulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Research 65(7):2684-2689